Compare Howmet Aerospace Inc (HWM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Viatris Inc — how do they compare? Howmet Aerospace Inc trades at $280.7 (market cap $111.63B), while Viatris Inc trades at $17.05 (market cap $20.50B). The key difference: Howmet Aerospace Inc is far larger — about 5.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| HWM | VTRS | |
|---|---|---|
Market Cap | $111.63B | $20.50B |
Sector | Industrials | Health |
52-Week High | $283.23 | $17.59 |
52-Week Low | $171.00 | $8.74 |
Enterprise Value | $113.88B | $32.71B |
Dividend Yield | 0.17% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $271.98, down 0.17% on the day, with technical indicators showing a neutral trend. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.22 beating expectations of $1.11, and robust profitability with a 20.22% net income margin. Recent news highlights strength in commercial aerospace demand driving growth prospects.
The outlook remains positive with 84% analyst buy ratings and a $317.63 consensus price target implying 17% upside. Key risks include premium valuation multiples and exposure to aerospace cycle volatility. Continued execution on commercial aerospace growth and defense contracts supports the bullish case, though investors should monitor Q2 2026 earnings due August 6 for confirmation.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
